In bladder and breast cancer, a network approach distinguished two different receptor protein signatures associated with the E2F1-mediated EMT, E2F1–TGFBR1–FGFR1 in bladder cancer and E2F1–TGFBR2–EGFR in breast cancer. Here, EGFR is linked to breast carcinoma.